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ABSTRACT
Implantable drug delivery systems have attracted a great deal of attention in recent
years. In these applications, usually active agents (e.g., drugs, growth hormones, etc.),
which are released in their environment, are loaded into a host hydrogel or polymeric
fibre and thus may provide a healthy environment and enhance regeneration of the
surrounding tissue. Although hydrogel structures have shown good efficiency in
releasing the different types of drugs, it is worth mentioning that due to their burst
release kinetics, they usually cannot be applied in controlled drug release systems.
Therefore, there are many attempts to develop new structures to overcome this
problem.
In this work, we introduce a coaxial wet-spinning method to develop novel
polycaprolactone (PCL)/alginate and PCL/chitosan coaxial fibres for future
application for controlled drug delivery. A coaxial wet-spinning assembly strategy is
proposed to readily prepare core-sheath fibrous structures. Fine and continuous coaxial
fibres with the sheath of polycaprolactone and core of alginate or chitosan were
prepared by necessary wet spinning conditions. By applying this procedure, coaxial
fibres with a broad compositional range and controllable diameters were fabricated.
The morphological and mechanical properties of these fibres were studied, with release
proﬁles from the coaxial ﬁbers determined using a model component. Our results
suggest that unlimited length of designed coaxial PCL/alginate and PCL/chitosan
fibres can be produced giving potential to create 3D textile structures. Moreover, these
designed coaxial fibres could be potential candidates for tissue engineering with the
feature of controlled drug delivery.
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1.1

INTRODUCTION AND LITERATURE REVIEW

Drug Delivery Systems

Drug delivery systems (DDS) describe a formulation or device that allows the
introduction of a therapeutic material into the body and advances its efficacy and safety
by regulating the amount, period, and location of drug release in the body. This
procedure comprises the administration of the therapeutic product, the release of the
active components by the product, and the later transport of the active components
through the biological membranes to the site of action. The method by which a drug is
delivered can have a significant effect on its efficacy. Conventional drug delivery
systems comprise injections, oral formulations (solutions, suspensions, tablets and
capsules), topical creams and ointments which are commonly used in practice. Among
those, oral administration is the most preferable route of administration, being
convenient, controlled by the patient and requiring no skilled medical intervention.
Such a simple route of delivery possesses many disadvantages. For example, many
drugs cannot be given by this route due to poor absorption characteristics with the
tendency to degrade in the gastrointestinal tract. A potential alternative way of
administering drugs via routes such as oral trans-mucosal, transdermal, nasal,
pulmonary, vaginal, ophthalmic, and central nervous system[1] have been developed to
overcome the limitation of oral drug delivery system. Improving the safety efficacy
ratio of conventional drug delivery has been attempted using different methods such
as individualizing drug therapy, dose titration, and therapeutic drug monitoring.
Delivering the drug at a controlled rate, slow delivery, and targeted delivery are other
very attractive methods which have been pursued vigorously.
Controlled release drug delivery systems represent one of the very important areas of
health care[3]. Different types of carrier base drug delivery systems have been designed
for this purpose such as liposomes, proliposomes, microspheres, gels, prodrugs, and
cyclodextrins. Liposomal drug delivery systems provide good control over infectious
diseases, cancer, lung-specific disease, brain tumours[4]. Compared to systemic
therapy, these delivery systems have several advantages, such as reduced toxicity,
better efficacy, and improved patient compliance. For example, systemic
chemotherapy usually requires administering high drug dosages in order to achieve
1

therapeutic effect due to the substantial loss of these drugs before they reach their
target cancer cells. Substantial loss of the administered drug can be due to partial
degradation and immediate drug excretion by body organs[2].
These high doses typically give rise to whole body toxicity as a result of the drug
absorption by other tissues and organs that entails devastating side effects. However,
limitations such as lower drug bioavailability and higher drug degradation and loss
have prompted the development of novel tools to enhance drug delivery, whereby the
specific targeting of cancer cells, through local drug delivery, would reduce systemic
related toxicities.
Many different drug delivery carriers have been investigated over the past three
decades which can be either injected or implanted in the body[5] such as natural
polymers[6,7], synthetic polymers[8], nanoparticles[9–12], microcapsules[13–15], and
polymeric implants[16,17]. Implanting medical devices through surgical procedure
improves millions of patients’ quality of life every year[18]. Development in DDS in
recent years has promoted the need for biomaterials with degradable properties.
Recently, synthetic and natural biodegradable polymers have attracted the attention of
researchers for the use as carriers for drug delivery[19,20] and medical devices. Table
1-1 lists some polymers used for medical devices.
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Natural Polymers

Table 1-1 Polymers used for implantable devices[20,21].
Polymers
Collagen

Applications
absorbable sutures, implantable contact
lenses, sponge wound dressing, drug
delivery system

Albumin

cell and drug microencapsulation, albuminbinding surfaces[22] for implantable devices

Poly (amino acids)

oligomeric drug carrier

Carboxymethyl cellulose

cell immobilization via a combination of
ionotropic gelation and polyelectrolyte
complex formation (e.g. with chitosan), in
drug-delivery systems and dialysis
membranes.

Alginate (marine sources, controlled release of bioactive substances,
algae)
injectable microcapsules for treating

Synthetic biodegradable Polymers

Chitosan
and
derivatives
Poly(lactic acid)

its controlled-delivery systems
sutures, drug delivery systems,
engineering, and implantable devices

tissue

poly(glycolic acid)

sutures, drug delivery systems,
engineering, and implantable devices

tissue

poly(-caprolactone)

drug-eluting stents, sutures, and implantable
devices

Poly(cyano acrylates)

drug delivery systems, surgical adhesives and
glues

Polytetrafluoroethylene

oxygenator membrane, vascular graft,
catheter coating, soft tissue augmentation,
vascular prostheses

Polymethylmethacrylate

dental restorations, intraocular lenses, joint
replacement, e.g. bone cements
orthopaedics, plastic surgery, cardiovascular
application, sutures, tissue engineering, and
drug delivery

Poly(dioxanone)

3

The spinning process enables fibre extrusion at room temperature with drugs and
therapeutic agents which can be incorporated in implant devices. For drug delivery,
fibres have additional advantages such as strong mechanical properties, positional
stability, uniform diameter, uniform drug concentration, and controlled release due to
the porosity of the fibrous structure. Furthermore, the devices can be readily mass
produced. Among the fibre manufacturing methods; melt spinning, electrospinning
and wet spinning, the latter offers the strongest fibres and the widest range of drugs
that can be incorporated into such a structure. However, this method uses organic
solvents which must be removed from the fibre. This can be done by the use of
different solvent baths. These manufacturing processes allow for tunable controlled
drug delivery[23]. A biodegradable drug-loaded fibre trademarked ELUTE® is
commercially available for pharmaceuticals (now TissueGen Company).
1.2

Fibre Spinning Technologies

The process of forming fibres from polymers (melt or gel) is referred to as “fibre
spinning”. Depending on the properties of the polymer (physical and chemical), there
are two general methods for fibre spinning; melt spinning and gel spinning. Gel
spinning itself can be divided into; dry spinning or wet spinning, based on the fibre
solidification process[24,25].
1.2.1

Wet-spinning

Wet spinning is a non-solvent-induced phase inversion technique where polymeric
fibres are produced through an immersion-precipitation process. This is the oldest
spinning method which was initially used for the spinning of rayon fibres[25]. In wet
spinning, the polymer solution is prepared in a suitable solvent, then extruded at a
controlled flow rate into a coagulation bath containing a non-solvent. Inward mass
transfer of the non-solvent and outward mass transfer of solvent in the filament inside
the coagulation bath results in the process of solidification. The coagulation rate
(influenced by the mass transfer rate between solvent and non-solvent) affects
morphology (i.e. cross-section) of the final fibre.
Figure 1-1 shows the schematic images of lab scale wet-spinning setup and rotary
coagulation bath. Aramid, acrylic, modified acrylic, polyaniline, and spandex can be
produced by the wet spinning process[26]. In addition, the development of wet-spun
4

fibres made of natural polymers such as chitosan[27], and regenerated silk fibron[28–30]
have been reported.
Wet-spun chitosan[31] and poly (L-lactic acid) (PLLA)[32] fibres have been used as drug
carrier/releasing devices. Chitosan fibres as well as PCL[33] and braided PLLA
fibres[34] have also been used in tissue engineering applications.
Biodegradable fibres for the controlled delivery of dexamethasone or levofloxacin
were studied by Mack et al.[35]. In their study, poly (lactide-co-glycolide) (PLGA)
fibres were prepared by wet-spinning solutions while the drug was dissolved in
dimethyl sulfoxide (DMSO) in a coagulation bath of water. Fibres loaded with
levofloxacin were implanted in the eyes of the New Zealand white rabbit, showing
effective levels of levofloxacin in the tears for 6 days[35].
PCL fibres with a hollow structure have the potential for many applications due to
their high porosity. Coaxial PCL/PEO hollow microfibres have been fabricated by
Rubert et.al[36]; in their study, Dexamethasone was encapsulated in highly porous
micro-fibres to regulate chronic inflammations[36]. Moreover, PCL hollow microfibres have previously been produced by phase separation methods using different
coagulation baths for vascular tissue engineering applications. These fibres are
promising scaffolds for small-calibre blood vessel regeneration[37].

5

Figure 1-1 Illustration of lab scale wet-spinning apparatus a) long bath coagulation
line and b) rotary coagulation bath.

1.2.2

Coaxial wet-spinning

Unlike the coaxial electrospinning technology that has been utilised to spin core-sheath
nanofibres, the coaxial wet-spinning approach is not a well-established method for the
preparation of coaxial microfibers. This is due to the extreme difficulty of selecting
desirable coagulation baths and harmonious solvents for inner and outer components.
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Using the coaxial system to obtain multi-layered fibres is quite a novel method in the
wet-spinning process.
Coaxial wet-spinning of alginate hollow fibres was reported by Hu et al[38]. In their
study, hollow and solid hydrogel fibres with different diameters were spun by a tripleorifice spinneret.
Another approach to create coaxial fibres has been described by Ucar et al[39]. They
produced a chitosan fibre core coated with alginate as a sheath. Gentamicin (a model
antibiotic) was incorporated into the scaffold and its release kinetics measured. These
scaffolds are potentially useful for tissue engineering with the feature of controlled
delivery of the bioactive agent[39].
Bio-polymeric core-sheath fibres incorporating an inner core of chitosan and alginate
as the sheath, were fabricated by Mirabedini et al.[40] to utilise as 3D tissue scaffolds
capable of drug delivery[40].One of the advantages of this coaxial method is the
utilisation of properties of both materials in the fibre, allowing it to be used in different
applications. For instance, materials with different hydrophilicity can be utilised to
overcome the solubility limitation of drugs[41].Another advantage is that burst release
kinetics of an encapsulated drug may be decreased, providing a longer, more sustained
release profile. For example, encapsulating the drug in a hydrogel based material and
thus protecting the structure by a hydrophobic surface can enhance the release profile
by sustained release[41].
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1.3

Synthetic Biodegradable Polymers

“Biomaterial” refers to classes of materials which interact with biological systems.
Polymers are a subset of biomaterials that can play a major role in human health system
due to their biocompatibility and biodegradability. The complexity and diversity of the
in vivo environment limits the types of materials that can be used in biomedical
applications, therefore, polymers with a diverse range of properties are needed.
Biodegradable polymers have been widely utilised and greatly facilitated the
development of biomedical applications in the past two decades due to their
biocompatibility and biodegradability[42]. There are a wide range of materials used in
biomedical applications including organic and inorganic chemicals and metal alloys.
Depending on the application, specific properties of biomaterials are required, for
example; cell adhesion and biocompatibility are required in tissue engineering.
According to their specific properties, polymers can be categorized into; polymers with
responsive activities and polymers with reactive groups. In particular, polymeric
biomaterials incorporating various functional groups, such as carboxyl, hydroxyl,
amino, ketal, bromo, chloro, carbon–carbon double bonds or triple bonds, etc., are
highly sought after.
Other polymers may be responsive to temperature, pH, or redox conditions. A number
of polypeptides bearing pendant ionizable groups such as poly(glutamic acid),
poly(aspartic acid), poly(histidine), poly(lysine) and poly(arginine) exhibit pHresponsive properties.
Poly (lactic acid) (PLA), poly (glycolic acid), poly (-caprolactone) (PCL) and their
copolymers are aliphatic polyesters and have been widely investigated for biomedical
applications due to their biodegradability, bioresorbability, and biocompatibility[19,42].
Poly--caprolactone (PCL), known for its excellent biostability and processability was
selected for investigation as part of this thesis and findings reported herein.
1.3.1

Polycaprolactone (PCL)

PCL is a linear aliphatic polyester and one of the earliest polymers synthesized by the
Carothers group in the early 1930s[43]. PCL can be produced by two methods;
condensation of 6-hydroxycaproic (6-hydroxyhexanioc) acid and ring opening
polymerization (ROP) of -caprolactone. The preferred method is ROP as it yields a
higher molecular weight polymer with lower polydispersity. Figure 1-2 outlines the
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four main mechanisms of ROP based on catalyst; anionic, cationic, monomeractivated, and coordination-insertion ROP. Anionic ROP results in formation of an
anionic species which then attacks the carbonyl carbon of the monomer. The carbonyl
oxygen of the monomer attacks the cationic species which is formed by cationic ROP.
In monomer–activated ROP the activated monomer attacks the polymer chain end. The
most common method of ROP involves coordination of the monomeric species to the
catalyst and insertion of the monomer into the metal-oxygen bond of the catalyst[44].
The average molecular weight of polycaprolactone varies from 3 to 80 kDa which can
be graded by molecular weight and changed, depending on sources and preparation
methods[45]. PCL is a semi-crystalline polymer with glass transition temperature (Tg)
of -60 ◦C and melting point range between 59 and 64 ◦C, dictated by the crystalline
nature of PCL which enables easy processing at relatively low temperatures[46].
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Figure 1-2 Mechanism of the initiation step for a) anionic[47], b) cationic[47,48], c)
monomer-activated[49,50],

and

d)

coordination-insertion

ring

opening

polymerization[47,48] (ROP) of ε-caprolactone to form polycaprolactone.
PCL is soluble in chloroform, dichloromethane (DCM), carbon tetrachloride, benzene,
toluene, cyclohexanone and 2-nitropropane at room temperature. However, higher
temperatures are needed for PCL to dissolve in 2-butanone, acetone, ethyl acetate,
dimethylformamide (DMF) and acetonitrile. PCL is insoluble in petroleum ether,
diethyl ether, and alcohols[51]. Due to its slow degradation, FDA approval, nontoxic
properties, ability to encapsulate many diverse drugs, and excellent tensile properties,
PCL has been investigated for use as a long term drug delivery device[19].
PCL can be applied to drug delivery as a microsphere or nanosphere[52]. Human basic
fibroblast growth factor (bFGF) loaded PCL-PEG-PCL nanoparticles have been
studied by Gou. M et al.

[53]

Such nanoparticles may have potential as anti-tumor

vaccines. Encapsulation efficacy of this nanoparticle has been reported as 61% which,
with an initial burst of approximately 60%, bFGF was released for 8 days with 70% of
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total bFGF release[53]. It can be also used as a membrane with incorporation of other
material as controlled release devices for bioactive molecules and extended-residence
support for cell growth. Other researchers showed that owing to its capability to deliver
bioactive molecules such as growth factors and hormones, PCL is able to deliver anticancer drugs for cancer treatment[54,55].
DOX-loaded (poly[ethylene glycol]--polycaprolactone) di-block copolymer (MP)
gel exhibited remarkable in vitro anti-proliferative activities against B16F10 cancer
cells. In vivo experiments employing B16F10 cancer cell xenograft-bearing mice
showed that a single intra-tumoral injection of DOX-loaded MP gel inhibited the
growth of tumours as effectively as repeated injections of free DOX, and more
effectively than a single dose of free DOX (Figure 1-3)[54]. This study was also
successful in reducing the DOX level in other organs consequently lower side-effects
were observed in comparison with free DOX injection.
PCL can also be utilised in medical devices as sutures[56,57], wound dressings[58],
contraceptive devices[59], fixation devices[60], and dentistry[61]. For example, the longterm contraceptive device Capronors® has been developed for the zero order release
of levonorgestrel and is composed of PCL[62]. PCL is also applied in tissue
engineering[63,33] and textile fabrication for tissue engineering of the aortic valve[64].
However, for tissue engineering purposes, PCL has some disadvantages such as a low
rate of degradation[43]. Nevertheless, the ability of PCL to be blended with other
polymers could potentially overcome this disadvantage. For example, biocompatible
and biodegradable PCL-sebacic acid (PCL-SA) blend was developed to increase the
degradation rate of PCL due to the higher degradation rate of sebacic acid[65].
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Figure 1-3 Inhibitory effects of saline, Doxorubicin-loaded (poly[ethylene glycol]-polycaprolactone) di-block copolymer MP, repeated injections of free DOX (0.4 mg)
and a single injection of DOX (0.4 mg)-loaded MP gel. The image of excised tumor
masses at the time of sacriﬁce after 1, 15, and 20 days post treatment from B16F10
cancer cells xenograft-bearing mice[54].
1.4

Hydrogels

Hydrogels are characterised as being three dimensional polymer networks containing
crosslinked (chemical or physical) hydrophilic polymer chains. Hydrogels readily
swell in aqueous solutions due to their hydrophilicity, however they do not dissolve
due to their cross-linked nature[66,67]. Hydrogen bonding, hydrophobic interactions and
crystalline formation are examples of physical crosslinks. The degree of chemical
cross-linking, which creates a covalently cross-linked network,[68] significantly effects
the physical and mechanical properties of hydrogels [68].
Most hydrogels will respond to some physiological stimuli present in the body such as
temperature[69,70], pH[71], and certain substances[72]. The hydrogels respond by
changing form, mostly reflected as a change in volume, due to a change in their water
content. Hydrogels have been of interest for use in biological applications due to their
capability of mimicking the appearance and properties of many soft, natural tissues[73].
Moreover, their properties such as flexibility, swelling, diffusion, and also their
mechanical and physical behaviour make them appealing as potential implantable drug
delivery systems[73–75]. To use hydrogels in a drug delivery application, their physical
12

and chemical properties such as permeability, biodegradability, and surface
functionality need to be fine-tuned. Some models have been previously advanced to
predict the release of an active agent from a hydrogel device over a period of time.
These models included diffusion-controlled, swelling-controlled, and chemicallycontrolled hydrogels[76].
Depending on their properties, hydrogels may exhibit different chemical and physical
interactions with drugs, giving rise to varying drug release mechanisms. Figure 1-4
outlines various controlled release mechanisms from hydrogels. Chitosan and alginate
were two selected hydrogels for study as part of this thesis due to their well know
properties which are discussed in following sections.
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Figure 1-4 Schematic illustration of various drug release mechanisms from
hydrogels[73]. a) Dissolved drug in polymer diffused out of hydrogel due to mass
transfer. Dissolution rate is commonly controlled by diffusion, b) release based on
polymer surface erosion and diffusion of drug into media, c) hydrogel containing drug
encapsulated in a secondary controlled release device such as liposomes,
nanoparticles, and micelles, d) swelling of hydrogel due to the ability of high water
intake led to increase in diffusion rate of drug.
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1.4.1

Chitosan

Chitosan is the deacetylated or partially deacetylated form of the natural polymer chitin
in the presence of alkaline substances. Chitin is sourced from the exoskeleton of
insects, crustaceans and fungi. It is a linear polysaccharide, composed of glucosamine
and N-acetyl glucosamine units linked by β (1–4) glycosidic bonds [77] (Figure 1-5).

Figure 1-5 Chemical structure of chitosan[78].
The structure of chitosan varies depending on the proportion of N-acetyl-Dglucosamine and D-glucosamine residues, with the content of glucosamine referred to
as “the degree of deacetylation (DD)”; directly effecting the chemical and biological
properties of the polymer as well as its molecular weight. Generally, when the DD of
chitin is higher than 50% it becomes soluble in an aqueous acidic medium (below pH
6.0). This is due to the protonation of amine groups which have a pKa value of 6.3
forming a water-soluble, cationic, polyelectrolyte chitosan. The presence of amino
groups indicate that pH substantially alters the charged state and therefore the
properties of chitosan[79] (Figure 1-6). The DD impacts on the biodegradability of this
polymer, for example, a DD above 69% decreases in vivo degradation of the
polymer[80,81]. Chitosan has unique and attractive properties for potential use in drug
delivery systems, such as low cost, availability (deacetylated from chitin, the second
most abundant natural polymer), biocompatibility, and biodegradability,[82] with its
degradation products being non-toxic, non-immunogenic and non-carcinogenic[83].
In-vitro degradation of chitosan occurs through the action of enzymes such as
chitosanase, lysozyme and papain[84,85]. The enzyme lysozyme is known to degrade
chitosan in-vivo through hydrolysis of the acetylated residues, with the rate of
degradation depending on the degree of acetylation and crystalline structure of the
chitosan [86].
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Figure 1-6 Schematic illustration of chitosan’s versatility. At low pH (< 6), chitosan’s
amine groups are protonated conferring polycationic behaviour to chitosan. At higher
pH (above about 6.5), chitosan’s amines are deprotonated and reactive. Also at higher
pH, chitosan can undergo inter-polymer associations that can lead to fibre and network
(i.e. film and gel) formation[79].
Chitosan is used in many applications, however its solubility in only a few dilute acid
solutions limits the ability to vary its mechanical properties. In order to increase
chitosan’s usage in many applications, chemically-modified chitosan derivatives have
been synthesized and reported[87]. For example, salicylic acid-grafted chitosan
oligosaccharide nanoparticle has been synthesised for Paclitaxel (anti-cancer drug)
delivery[88].
The interest in chitosan for drug delivery applications arises mainly from the fact that
this natural polysaccharide allows for the production of biocompatible and
biodegradable structures. Chitosan has been found to be non-toxic[58] and is an FDA
approved food additive. Biocompatibility, biodegradability, and the ability to impart a
positive charge allowing it to interact with negatively charged glycosaminoglycans
present in the extracellular matrix, are some of the advantageous properties of this
polymer in drug delivery systems[89]. Moreover, avoiding the need to use hazardous
organic solvents make chitosan a suitable choice for fabricating particles since it is
soluble in aqueous acidic solutions[90].
Chitosan-based structures have been widely utilised in the delivery of active agents
and drugs to ocular systems[91], protein/peptides for nasal delivery

[92–95]

, and anti-

cancer drugs for targeted cancer therapy[96–98]. Chitosan-coated super-paramagnetic
iron oxide nanoparticles (CS MNPs) were synthesized in situ as nanocarrier systems
16

and loaded with the drug Bortezomib (Velcade) by Unsoy et al.[99] This study reported
that the pH-responsive magnetic targeting of Bortezomib was more efficacious than
free drug treatment. Moreover, targeted delivery of Bortezomib reduced the frequency
of drug administration by lowering the required amount of drug dosed. The use of
chitosan in this nanoparticle helped to modify the surface properties of the magnetic
core structure and improved the biodegradation profile[100].
1.4.2

Alginate

Alginic acid, (also called algin or Alginate) is derived from brown algae
(Phaeophyceae), including Laminaria hyperborea, Laminaria digitata, Laminaria
japonica, Ascophyllum nodosum, and Macrocystis pyrifera[101]. Alginate is a linear,
unbranched polysaccharide composed of monomers of β-D Mannuronic acid (M) and
its C-5 epimer α-L-guluronic acid (G) residues covalently linked by (1-4) glycol
bonds[102] (Figure 1-7). Addition of alcohol to alginic acid and followed by sodium
carbonate, converts the alginic acid into sodium alginate. The viscosity of alginate
solutions vary widely depending on the molecular weight of the polymer which can
range from 80 kDa to 290 kDa[103]. Alginic acid is sparingly soluble in water, soluble
in alkaline solutions but insoluble in most organic solvents. It is able to absorb 200–
300 times its weight in water. The solubility of alginic acid depends on the presence
of anionic groups within the polysaccharide. Sodium alginate is slowly soluble in cold
water, resulting in viscous solutions. However, it is insoluble in alcohol and organic
solutions. On the other hand, calcium alginate is practically insoluble in water and
organic solvents but soluble in sodium citrate[104].

Figure 1-7 Chemical structure of alginate[105].
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Alginate gels cross-linked by Ca2+can be degraded by removal of Ca2+. Removal of
Ca2+ can occur by the use of either a chelating agent such as ethylene glycol-bis (amino ethyl ether)-N, N, N’, N’-tetra acetic acid (EGTA), citrate, and phosphate or by
the presence of a high concentration of ions such as Na+ or Mg2+. This process
decreases the cross-linking of the gel and therefore gels are undermined. Alginate gels
also degrade and precipitate in 0.1 M phosphate buffer solution forming a calcium
phosphate precipitate, releasing entrapped materials within the gel[106].
Alginate gels have been widely used as biomaterials due to their biocompatibility
which was studied by injecting calcium alginate into kidney capsules of rats.[107].
Alginate gels have also been used as tissue engineering scaffolds, models for
extracellular matrices and drug delivery vehicles[108]. The advantages of alginate as a
matrix for immobilisation or encapsulation of drugs, bioactive molecules or controlled
release are its biodegradability, readily availability, non-toxicity, and water solubility.
The capability of sodium alginate to be cross-linked with a variety of cross-linking
agents is one of the important advantages of alginate which is used to delay the release
of some drugs[104]. Alginate can be simply altered via chemical and physical reactions
to achieve derivatives with different structures, properties, and therefore applications.
Alginate can also be prepared in three-dimensional scaffolding materials such as
hydrogels, microspheres, nanoparticles, sponges, foams and fibres[105]. For example,
hybrid alginate/CaCO3 nanoparticles prepared by Wu.J et al.[109] were capable of
sustained delivery of a hydrophilic drug (doxorubicin hydrochloride, DOX) and a
hydrophobic drug (paclitaxel, PTX) into tumour cells. The presence of alginate could
control the morphology and size of the nanoparticles[109].
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2

MATERIALS

Polycaprolactone (PCL, 80 kDa, Ref. 440744 Sigma-Aldrich) pellets, and Chitosan
(medium molecular weight of about approx. 450 kDa, Ref.448877 Sigma-Aldrich with
degree of deacetylation of ca. 80.0%) and alginic acid sodium salt from brown algae
(medium molecular weight), Toluidine blue O (also known as toluidine blue or TB),
calcium carbonate anhydrous, glucono-δ-lactone (GDL), and Phosphate buffered
saline (PBS, pH 7.4) were purchased from Sigma–Aldrich (Australia). Acetic acid,
acetone, methanol, ethanol, isopropanol, chloroform, N,N-dimethylformamide
(DMF), tetrahydrofuran (THF), Dichloromethane (DCM) sodium hydroxide pellets
were supplied from Ajax Finechem (Australia). Calcium chloride dihydrate from
Chem-supply and genipin from challenge bioproducts (Taiwan) were purchased.
2.1

Fabrication of wet-spun fibre

In this section, the process used in this work for fabricating the wet-spun fibres is
explained. It consists of multiple stages that are detailed as follows.
2.1.1

Spinning solution preparation

PCL spinning solutions were prepared by dissolving PCL pellets in the desired solvent
(acetone, THF, Dichloromethane, and chloroform) over 24 h by constant stirring. PCL
pellets were dissolved in DMF at 50 ºC with constant stirring to obtain PCL spinning
solution. Spinning solutions were prepared in each solvent with concentration various
from 5 to 20% w/v.
Chitosan solutions (3% (w/v)) were prepared in water containing 2.5% (v/v) acetic
acid. The mixture was stirred at 50 ºC for 24 h.
Alginate (3.5% (w/v)) was made by adding the alginate sodium salt powder into water
and stirring for 24 h at 50 ºC.
In the fabrication of the coaxial fibres, three solutions were prepared; alginate, chitosan
(as a hydrogel core), and PCL as the sheath. Alginate (3.5% w/v) was prepared in
water, whilst 3% w/v chitosan solution was prepared by mixing medium molecular
weight chitosan with deionized water and 2.5% v/v acetic acid. PCL (15% (w/v))
dissolved in DMF were used as the sheath. Spinning solutions were placed in a 10 mL
syringe held at RT (room temperature) for a period of time prior to spinning in order
to remove air bubbles.
19

2.1.2

Coagulation bath preparation

PCL coagulation baths were selected depending on the solvents of PCL. Water used
as a coagulation bath for wet spinning of PCL dissolved in DMF which is labelled in
this thesis as PCL-DMF/water (PCL-solvent/non-solvent). Coagulation bath of PCL
dissolved in acetone was water/ethanol 70/30 v/v which is labelled PCLacetone/water-ethanol 70/30 v/v. Non-solvent used for spinning of PCL dissolved in
DCM and chloroform was methanol/water 70/30 v/v which is shown in this thesis as
PCL-DCM/ MeOH-water 70/30 v/v and PCL-chloroform/MeOH-water 70/30 v/v.
1M NaOH in 10% v/v EtOH was used as coagulation bath of chitosan and 2% w/v
CaCl2 in 20% v/v EtOH coagulation bath used for wet-spinning of alginate fibres.
2% w/v CaCl2 and 1M NaOH coagulation bath was used to spin PCL/Alg and PCL/CS
coaxial fibres, respectively.
Washing processes were performed during the spinning and after collecting the fibres.
Fibres were washed with 70% v/v EtOH then dried on the collector at room
temperature. The washing process was performed after collecting all the fibres on
collector for second time before drying.
2.1.3

Fibre spinning

The coaxial wet-spinning setup was similar to that used for conventional wet-spinning,
however, two syringe pumps (KD Scientific KDS100) and coaxial spinneret were
used. The prepared spinning solutions were delivered by syringe using syringe pumps
and the syringes connected to the coaxial spinneret. The spinneret was placed into the
coagulation bath in a way that the nozzles were completely immersed in the
coagulation bath as shown in Figure 2-1.
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Figure 2-1 Image of coaxial wet-spinning set-up which two syringes on two syringe
pumps connected to spinneret in the coagulation bath.
Fibres extruded from the end of the spinneret were either washed and collected or
stretched by a stretching roller to obtain improved mechanical properties. Figure 2-2
shows the schematic image of the co-axial wet-spinning setup. The collector speed
was adjusted to 35 rpm in all spinning methods. Syringe pumps were set to a defined
flow rate for both core and sheath. The flow rate varied based on the polymer
properties. Table 2-1 and Table 2-2 show the different flow rates that were utilised
for the fabrication of different types of fibres.

Figure 2-2 A schematic image of co-axial wet-spinning setup. a) Syringe pumps were
used to pump b) spinning solutions at a specific flow rate into the spinneret placed in
the c) coagulation bath. The fibre formed in the bath was stretched by a stretching
roller then the fibre passed through the d) wash bath and finally collected by the e)
collector.
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Table 2-1 Flow rate of different solutions used for fibre spinning
Fibres
PCL
PCL hollow

Conc. (% w/v)
15
15

Coagulation bath
Water
Water

Alginate

3.5

2% CaCl2 in 20%
v/v EtOH

Chitosan

2
3
4

1M NaOH in 10%
v/v EtOH

Flow rate (mL.h-1)
10
15
5
15
50
25
25
25

Table 2-2 Flow rate of different solutions used for the spinning of coaxial fibres

Coaxial
Fibres

PCL
Conc.
(%w/v)

Hydrogel
Conc.
(%w/v)

Coagulation
bath

PCL/Alg

15

3.5

2% CaCl2

PCL/CS

15

3

1 M NaOH

Flow rate
of Core
(mL.h-1)
10
10
20
100
200
100
200
5
15

Flow rate
of sheath
(mL.h-1)
10
10
10
30
30
40
40
25
25

2.1.3.1 Coaxial Spinneret
A stainless steel pre-designed coaxial spinneret was used to spin coaxial fibres. Two
syringes were connected to the spinneret ports via teflon tubes. The spinneret consisted
of an inner nozzle and outer nozzle ( Figure 2-3 (c)) with two ports which allowed for
extrusion of two fluids into a coagulation bath[40]. Figure 2-3 (a and b) show the
spinneret and nozzle with measured diameters. The inner nozzle was positioned
exactly in the centre and was adjusted by modulating the bolts on the spinneret. This
process must be performed with an optical microscope and prior to spinning.
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Figure 2-3 a) Microscopic image of spinneret’s nozzle, and b) photo of the spinneret,
and c) cross-section of coaxial spinneret (blue port: sheath, and pink port: core).
2.2

Characterisation of as-prepared fibres

In order to characterise the fibres properties, different methods as listed in the
following sections were used. They are briefly explained in this section.
2.2.1

Differential Scanning Calorimetry

Differential Scanning Calorimetry (DSC) analysis was performed on a DSC Q100, TA
Instruments. The constant heating rate of 10 ºC min-1 was applied on fibres (5-10 mg)
packed in aluminium pans (internal volume of 10 µL) under a nitrogen flow. The
samples were first heated to above the melting temperature of the polymer (100 ºC)
and held at that temperature for 5 min to erase the thermal history, then cooled to 0 °C
and reheated again to 100 °C. The melting temperature (Tm) and the melting enthalpy
(ΔH) of PCL were determined from the first and second heating scans. The
crystallinity degree (Xc) can be calculated by applying equation (1)[110]
% 𝐶𝑟𝑦𝑠𝑡𝑎𝑙𝑙𝑖𝑛𝑖𝑡𝑦 =

𝛥𝐻𝑚
∗ 100 %
𝛥𝐻𝑚°

:
(1)

where ΔH0m is the melting enthalpy of 100% crystalline PCL, which is 139.5 Jg-1[111]
and the sample melting enthalpy, ΔHm, was determined by integrating the areas (J/g)
under the peaks.
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2.2.2

Stereo microscopy analysis

The average PCL fibre diameter was determined using a LEICA m205A stereo
microscope. Fibre diameters were measured at least 5 times on four fibres of each type
in stereomicroscope image. The average diameters are reported as the average ±
standard deviation. The morphology of cross-section of coaxial fibres was observed in
liquid nitrogen by optical microscope. Sample holders were placed in petri dishes with
liquid nitrogen to avoid sample dehydration while imaging by microscope.
2.2.3

Scanning electron microscopy (SEM) analysis

LVSEM (low vacuum scanning electron microscopy) in a JSM-6510LV device was
used in order to analyse overall surface, cross-section morphology, and diameter
developed fibres. Analysis was performed at an accelerating voltage of 15 kV at
magnification between 100x and 10000x. The sample preparation for SEM analysis is
as follows for different samples: Dry samples were prepared by cutting them in liquid
nitrogen using a sterile surgical blade and coated with platinum while wet fibres were
prepared by freezing samples in liquid nitrogen for 45 seconds and then cutting with
blade and immediately placed in LV-SEM chamber. Cross-section samples were not
coated with platinum.
2.2.4

Mechanical Properties Test

Tensile testing was carried out using EZ-L Tester from Shimadzu, Japan with a 10 N
load cell, using a crosshead speed (V1) of 5 mm/min and a gauge length of 10 mm at
room temperature. Chitosan and alginate samples were mounted on an aperture card
(1.0 cm length frame) with super glue. Average Young's modulus and ultimate tensile
stress were determined after testing four times for each type of fibre. Young’s modulus
obtained from stress-strain curve according to the equation (2):
𝐸=

𝜎
𝜀

(2)

Where 𝐸 is Young’s modulus, 𝜎 is stress generated by load, and 𝜀 is applied strain.
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2.2.5

In vitro Toluidine Blue (TB) release study

The profile of TB release from wet-spun fibres was determined by collection of TB
aliquots in phosphate-buffered saline PBS at varying time points (0-300 h). The release
medium was collected by micropipette at specific time points and replaced with the
same volume of fresh PBS (total volume of 1 mL). Fibres were placed in 1.5 mL vials
with 1 mL of PBS in U-shape to avoid contacting the fibre ends with the medium.
Vials containing fibre and PBS were incubated at 37 °C and spun at 50 rpm. The
amount of released TB was determined using a Shimadzu UV 1601 spectrophotometer.
In order to construct the absorption/concentration calibration curve, a standard curve
of TB in PBS (0.01µg/mL to 10 µg/mL) was generated and the absorbance of TB at
its λmax 630 nm (by UV-Vis spectroscopy) was monitored.
The TB loading efficiency was estimated by placing 1 cm of fibre containing TB in
PBS for 2 months. TB release data were reported as a percentage of release (Mt)
relative to total TB loading (Mtot).
2.2.6

Rheology

Gelation study was conducted with a rheometer (TA Instruments AR-G2) using a
cone-plate geometry (cone angle 2º, diameter 40mm, and truncation 55µm). Liquid
samples were transferred into the cell immediately after mixing (t = 0). Time sweeping
procedure was used to test samples and measurement stopped at 500 min. Storage
moduli G′ and loss moduli G′′ were monitored as a function of time at a 1 Hz frequency
and a 0.1% strain under constant temperature at 15 °C. Gelation time was determined
by the cross point of G′ and G′′.
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3
3.1

RESULTS AND DISCUSSION

PCL solvent selection

The solubility of PCL was tested in a range of organic solvents as shown in Table 3-1.
PCL was found to be soluble in DMF and acetone at 50 °C; DCM, chloroform, and
THF at room temperature, but insoluble in EtOH, MeOH, and IPA.
Table 3-1 Solubility of PCL in a range of solvents
Solvent Type

PCL solubility

Temperature

N,N-Dimethylformamide

Yes

50 °C

Acetone

Yes

50 °C

Tetrahydrofuran (THF)

Yes

RT

Dichloromethane (DCM)

Yes

RT

Chloroform

Yes

RT

Ethanol (EtOH)

No

RT

Methanol (MeOH)

No

RT

Isopropanol (IPA)

No

RT

Water

No

RT / 50°C

(DMF)

Due to the limited solubility of PCL in some solvents, water/ethanol (70/30 v/v),
methanol/water (70/30 v/v), and water were used as non-solvents for PCL dissolved
in DMF, acetone, DCM, and chloroform respectively[112] (Table 3-3). This
solvent/non-solvent interaction was critical to induce precipitation of the injected PCL
in order to form the fibre.
3.2

PCL concentration selection

Fibre “spinnability” is a function of the PCL solution injection flow rate, PCL
concentration, and solvent/non-solvent system. Hence, a systematic study was
performed to find out the effect of spinning conditions on spinnability of PCL solutions
in order to optimise wet-spinning conditions. Different concentrations of PCL (5 to
20% w/v) were prepared in organic solvents including DMF, acetone, DCM, and
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chloroform and spun into water, water/EtOH (70/30 v/v), MeOH/water (70/30 v/v),
and MeOH/water (70/30 v/v) at a flow rate of 10 mL.h-1 (Table 3-2).
According to results presented in Table 3-2, PCL solutions of ≤10% w/v concentration
were not suitable for wet-spinning since they produced fibres which were non-uniform
in diameter and short in length. This was most likely due to the visually low viscosity
of PCL solutions at this concentration. When the concentration was increased to 20%
w/v it was also observed that fibres were not readily spun when PCL solutions were
prepared using DMF, acetone, and DCM/co-solvent solutions, resulting in the fibres
exhibiting lumps which may be due to the very visually high viscosity of these PCL
spinning solutions. However, 20% w/v PCL dissolved in chloroform was shown to
have a suitable viscosity for successful spinning, producing uniform fibres. From the
data presented in Table 3-2, it appears that a PCL concentration of 15% w/v PCL
prepared in DMF, acetone, and DCM solvents, resulted in formation of continuous
fibres. PCL (15% w/v) dissolved in chloroform was not spinnable, therefore solutions
containing 20% w/v PCL dissolved in chloroform, were utilised for wet-spinning.
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Table 3-2 Spinnability of PCL in different solvents by varying the PCL concentration.
(Non-solvent of DMF: water, acetone: water/EtOH (70/30 v/v), DCM: MeOH/water
(70/30 v/v), and chloroform: MeOH/water (70/30 v/v)
Concentration (%w/v)
5

Solvent type
N,N-Dimethylformamide

PCL Spinnability
No

(DMF)

10

Acetone

No

Dichloromethane (DCM)

No

Chloroform

No

N,N-Dimethylformamide

Yes (non-uniform)

(DMF)

15

Acetone

Yes (slow production)

Dichloromethane (DCM)

Yes (non-uniform)

Chloroform

No

N,N-Dimethylformamide

Yes

(DMF)

20

Acetone

Yes

Dichloromethane (DCM)

Yes (slow production)

Chloroform

Yes (non-uniform)

N,N-Dimethylformamide

Yes (Lump formation)

(DMF)
Acetone

Yes (Lump formation)

Dichloromethane (DCM)

Yes (Lump formation)

Chloroform

Yes (non-uniform, slow
production)
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3.3

PCL Non-solvent Selection

Different types of non-solvents were examined in order to optimize spinning
conditions. Table 3-3 lists non-solvents used to wet-spin PCL fibres in various
solvents. From the results, PCL-DMF/water (PCL-solvent/non-solvent), PCLacetone/water-EtOH (70/30 v/v), PCL-DCM/MeOH-water (70/30 v/v), and PCLchloroform/MeOH/water (70/30 v/v) were selected as desirable solvent/non-solvent
systems.
Table 3-3 Spinnability of PCL solutions at solvent/non-solvent systems. (PCL
concentration: 15% w/v)
Solvent Type

Non-solvent Type

Spinnability

N,N-Dimethylformamide

Water

Spinnable

(DMF)

IPA

Not Spinnable

EtOH

Not Spinnable

Water

Not Spinnable

IPA

Not Spinnable

EtOH

Not Spinnable

Water/ethanol (70/30 v/v)

Spinnable

Water

Not Spinnable

IPA

Not Spinnable

EtOH

Not Spinnable

MeOH

Not Spinnable

Methanol/water(70/30 v/v)

Spinnable

Water

Not Spinnable

IPA

Not Spinnable

EtOH

Not Spinnable

MeOH

Not Spinnable

Methanol/water (70/30 v/v)

Not Spinnable

Acetone

Dichloromethane (DCM)

Chloroform
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3.4

Effect of solvent/non-solvent selection on the morphology of fibres

There were differences in the diameters of fibres produced using three different
solvents and a constant PCL concentration of 15% w/v, as shown in Figure 3-1. The
diameter of fibre is influenced by the solidification rate; due to acetone having a higher
volatility than DMF, solvent extraction occurs quickly, resulting in a higher mass
transfer rate which leads to a decrease in the flow rate of the jet into the coagulation
bath and consequently fibres with a larger diameter are formed[113]. Wet spun fibres
produced from a DMF solution have a higher coagulation rate due to the rapid mass
transfer which occurs between DMF and water, resulting in fibres with a larger
diameter (479.7 ± 4.6 µm). However, wet-spun fibres obtained from an acetone
solution have a lower coagulation rate compared to DMF, therefore fibres having a
smaller diameter were formed (326.5 ± 3.3 µm). In the case of wet-spun fibres from a
DCM solution, the mass transfer was very slow. Therefore, the fibres were maintained
in the coagulation bath for a period of time in order to complete the solidification
process. Consequently, wet-spun PCL fibres produced from DCM have the smallest
diameter compared with the other fibres (205.0 ± 2.6 µm). Figure 3-2 shows the
optical images of fibres facilitated to measure the average diameter of each fibre. PCL
dissolved in chloroform was omitted since it had a different concentration compared
to the above prepared samples which had diameters of 161.3 ± 47.4 µm. In addition,
the wet-spun PCL fibres obtained from chloroform were non-uniform, whereas those
from the above-mentioned fibres were (as observed from the optical images and the
standard deviation from measurements of diameters).
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Figure 3-1 The effect of solvent used to form a 15% w/v PCL solution and coagulation
non-solvent on PCL fibre diameter. PCL–DMF/water and PCL-acetone/water-EtOH
(70/30 v/v). Diameters of the fibres were measured at least 5 times on fibres using a
stereomicroscope.
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Figure 3-2 Optical microscopic images of fibres, a) PCL-DMF/water, b) PCLacetone/EtOH-water, c) PCL-DCM/MeOH-water and d) PCL-chloroform/MeOH337.6 µm

water.
Scanning Electron Microscopy (SEM) was used to study the effect of solvent/nonsolvent on the morphology of PCL fibres. Figure 3-3 shows the effect of solvents and
coagulants on the cross-section of fibres. These fibres are circular in their shape, and
their level of porosity differs significantly depending on the solvent in which they are
dissolved. For example, PCL dissolved in DMF and water (used as non-solvent) had
large and longitudinal pores, however PCL fibres with methanol/water non-solvent
showed a smoother cross-section (with a few circular pores created due to either the
presence of bubbles in solution or from solvent evaporation during the phase
inversion). Evaporation of solvent from the fibre and solidification of the dissolved
polymer occur simultaneously. Solidification begins from the outer surface of the
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solution and gradually propagates towards the centre of the fibre[114]. Coagulant,
solvent, and coagulation rate are the most important factors in determining fibre
morphology in the wet-spinning process. This is most likely due to the difference in
the mass transfer rate of solvent and coagulant during the coagulation process. A faster
transfer rate between the solvent and non-solvent results in a fibre with a porous
structure, whereas a slower transfer rate gives fibres with a denser structure[115]. The
coagulation rate in PCL fibres with DMF as solvent and water as non-solvent was high
with the fibre formed with an initial skin layer followed by the formation of the fibre
itself. The large porous PCL fibres formed in DMF illustrates this finding (Figure 3-3
(a)). However, the coagulation rate in PCL dissolved in acetone was not as rapid as
PCL in DMF, therefore, a fibre having a smaller porosity was formed during the
coagulation process (Figure 3-3 (c)). PCL fibres dissolved in DCM or chloroform had
the slowest coagulation rate in this study. These fibres remained in the coagulation
bath for a while in order to obtain solid fibres, resulting in fibres with an irregular and
denser structure as shown in Figure 3-3 (e and g).
The fibre cross section is determined by the mass transfer between the solvent and
non-solvent[24]. With the same injection flow changing the solvent/non-solvent system
has a significant impact on the fibre diameter. A lower solvent/non-solvent mass
transfer ratio generates fibres with circular cross-section fibres. For example when the
mass transfer rate (∆k) of the solvent is less than that of the coagulant (∆k < 0), the
filament swells and a circular cross section can be observed.
At a higher solvent/non-solvent mass transfer ratio (∆k > 0), the cross-section depends
on the mechanical behaviour of the coagulated layer. A soft layer results shrinks
leading to a circular cross section. In contrast, a rigid surface layer may fail leading to
a noncircular and irregular shape[116]. A porous cross-section is an advantage for drug
release. Hence PCL dissolved in DMF and acetone with porous structure could be
suitable candidates for drug release.
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.
Figure 3-3 SEM images of wet-spun PCL fibres in dry state. a) cross-section of 15%
w/v PCL-DMF/water, b) surface of 15% w/v PCL-DMF/water, c) cross-section of
15% w/v PCL-acetone/water-EtOH (70/30 v/v), d) surface of 15% w/v PCLacetone/water-EtOH (70/30 v/v), e) cross-section of 15% w/v PCL-DCM/MeOHwater (70/30 v/v), f) surface of 15% w/v PCL-DCM/MeOH-water (70/30 v/v), g)
cross-section of 20% w/v PCL-chloroform/methanol-water (70/30 v/v), h) surface of
20% w/v PCL-chloroform/methanol-water (70/30 v/v).
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3.4.1

Mechanical Properties of PCL fibres

The effect of solvent/non-solvent coagulation systems on the tensile properties of PCL
fibres using three different solvents was investigated. Figure 3-4 shows the stressstrain curves for PCL wet-spun fibres under different solvent/non-solvent conditions.
The mechanical properties of wet-spun PCL fibres in different solvent/non-solvent
systems were characterized by an initial linear region at low values of strain, followed
by two further regions of varying stiffness. Since PCL is a flexible fibre, the initial
stiffness response is not shown in the stress-strain curve. A distinct orientated, fibrillar
morphology was produced at high strain which indicated a high degree of structural
deformation and alignment induced by the process of drawing. The major influence of
solvent/non-solvent on the tensile properties of wet-spun fibres is shown in Figure
3-5. PCL wet-spun fibres produced in DMF as solvent and water as non-solvent had
the lowest modulus of 18.2 ± 1.2 MPa, whereas PCL wet-spun fibres produced in
DCM solvent and methanol/water as non-solvent had the highest modulus of 214.9 ±
55.1 MPa (P = 0.0004). PCL fibres produced in acetone as a solvent and water/ethanol
as non-solvent gave 98.9 ± 14.3 MPa Young’s modulus. The ultimate tensile strength
of fibres was also at its highest 112.1 ± 12.4 MPa when DCM was used as a solvent
for PCL and methanol/water as non-solvent and at its lowest 1.2 ± 0.3 MPa in the case
of DMF/water solvent/non-solvent system (P < 0.0001). In the case of acetone as the
solvent for PCL fibres and water/ethanol as non-solvent, the ultimate tensile strength
of fibres was 8.78 ± 2.4 MPa. Changing the solvent/non-solvent system also had a
slight effect on the elongation at break of fibres resulting in highest elongation at break
548.4 ± 178.3% in the case of acetone as the solvent for PCL wet-spun fibres and
lowest elongation break of 325.1 ± 178.3% for PCL wet-spun fibres produced in DCM
solvents (P = 0.1269). PCL wet-spun fibres in DMF/water solvent/non-solvent system
had 463.4 ± 117.4% elongation at break.
The Young’s modulus of wet-spun fibres are influenced by the mass transfer rate
between the solvent and non-solvent[116]. A higher mass transfer results in lower
structural ordering and therefore lower values of Young’s modulus. In contrast, tensile
strength and elongation at break at higher strains depends on the formation of porous
or dense structure of the fibre. Consequently, PCL fibres produced in DMF/water
solvent/non-solvent systems have the largest mass transfer and therefore lowest
modulus. Higher mass transfer leads to the formation of soft layers (lower modulus)
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of fibre. On the other hand, formation of rigid layers of fibre in DCM solvent and
methanol/water non-solvent raises the modulus of fibres. Production of denser fibres
resulted in an increase in tensile strength and decrease in elongation at break.
The results obtained demonstrate that fibres generated from PCL in DMF could
potentially be used in tissue engineering applications since they have a lower Young’s
modulus value and soft tissues (muscle, nerves, and blood vessels) also exhibit
significantly lower Young’s modulus values.

Figure 3-4 Stress-strain curve for tensile tests on PCL fibres spun in different
solvent/non-solvent system (15% w/v PCL-DMF/water, PCL-acetone/water-ethanol
(70/30 v/v), and PCL-DCM/methanol-water (70/30 v/v)). Inset: stress-strain curve for
tensile test of fibres at the initial 10% strain.
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a)

b)

*

*

c)

**

Figure 3-5 Effect of solvent/non-solvent systems on mechanical properties of 15%
w/v

PCL-DMF/water,

PCL-acetone/water-EtOH

(70/30

v/v),

and

PCL-

DCM/MeOH/water (70/30) fibres: a) Young’s modulus, b) ultimate tensile strength,
and c) elongation at break (*p<0.05, **p>0.05)
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3.5

Thermal properties of PCL fibres

The PCL fibres which exhibited the best properties (i.e. those dissolved in DMF and
acetone) were further characterised by thermal analysis (Figure 3-6). The thermal
characteristics of these wet-spun fibres were compared with those of PCL pellets,
shown in
Table 3-4. Using the enthalpy values from the melting peaks, the degree of
crystallinity of the PCL fibre was calculated using Equation (1). The samples were
heated to above the melting temperature of the polymer (100 ºC), then cooled to 0 °C,
and then reheated again to 100 °C. The first stage of heating was used to observe any
effect the processing method had on development of the PCL structure. The melting
temperature of PCL in acetone was lower than that for pure PCL and PCL in DMF. A
possible reason could be due to the growth of the lamella thickness or increase in the
Gibbs free energy.
The Tm (melting temperature) remained fairly constant over the heating/cooling
processes, however, slight increases in the level of crystallinity of PCL fibres suggests
a formation of crystalline lamellae during dissolution and the wet-spinning process.
Also, the melting point did not change significantly when changing the solvent (Figure
3-6).
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Figure 3-6 Differential scanning calorimetry curves of PCL fibres produced with two
different solvents (DMF and acetone) and non-solvents (water and water/EtOH
(70/30)) compared with PCL pellets. The process of wet-spinning generally has a
slight effect on the crystallization temperature of the PCL.
Table 3-4 Thermal properties of wet-spun PCL fibres
ΔHm (J/g)

1st Scan Melt

2nd Scan Melt

peak

peak

temperature

temperature

(⁰C)

(⁰C)

PCL pellets

60.2

59.7

58.9

42.2

PCL fibre in

59.9

58.5

76.3

54.7

64.9

59.3

75.6

54.2

Samples

Crystallinity
(%)

acetone
PCL fibre in
DMF

39

3.6
3.6.1

Wet-spinning of hydrogel fibres
Chitosan Fibres

Chitosan (2-4% w/v) of a medium molecular weight was prepared in water/2.5% v/v
acetic acid at varying concentrations. The acid protonates the free amine group present
in chitosan, making it soluble in weakly acidic solutions (pH ≤5.0) [117].
3.6.1.1 Wet-spinning of chitosan fibres
Chitosan fibres can be formed using both the rotary and horizontal coagulation
systems, however only the rotary system was explored in this work (Figure 3-7). This
method was chosen since it consumes less non-solvent in comparison with the
horizontal procedure.
It is necessary to use a strong alkaline solution to form chitosan structures; under such
conditions chitosan is deprotonated, making it insoluble, and consequently coagulation
occurs. Therefore, a solution of 1M NaOH and 10% v/v EtOH was used in the
coagulation bath (with a collecting speed of 30-60 rpm). EtOH was used to accelerate
the coagulation process by dehydrating the chitosan.

Figure 3-7 Schematic image of rotary coagulation bath.
The spinnability of chitosan at various concentrations, under the same injection flow
rate was tested. At a concentration of 3% w/v it was possible to successfully spin and
collect chitosan fibres continuously. However, at 2% w/v, fibre formation was slow,
resulting in a dried fibre with poor mechanical properties which could not be collected
continuously (Figure 3-10). At a concentration of 4% w/v chitosan, the solution was
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highly viscous and difficult to spin to form a continuous fibre. Table 3-5 compares the
spinnability of chitosan at various concentrations spun into NaOH/EtOH.
Table 3-5 Comparison of spinnability of chitosan at constant flow rate of 25 mL.h-1.
Chitosan Conc.

Injection Flow Rate

Spinnability

(%w/v)

(mL.h-1)

2

25

Yes (slow production)

3

25

Yes

4

25

Yes (bumpy)

Figure 3-8 shows the optical image of 3% w/v chitosan fibre after drying at room
temperature. The diameter of the fibre in dry state is 193.6 ± 6.1 µm. Upon hydration
in water the fibre diameter increased to 811.3 ± 12.2 µm.

Figure 3-8 Optical image of 3% w/v chitosan wet-spun fibre (25 mL.h-1 flow rate).
3.6.1.2 Morphological properties of chitosan wet-spun fibre
Scanning electron microscopy (SEM) was used to determine the morphology of
chitosan fibres in both the wet and dry state. It was obvious that chitosan has a smooth,
uniform cross-section and surface area (Figure 3-9 (d and e)) in the dry state.
However, Figure 3-9 (b) shows a porous cross-section structure (inset Figure 3-9a) of
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chitosan fibre in hydrated state with a smooth surface area. Analysis of fibre
morphology in the wet state must be carried out quickly as dehydration can occur while
the sample is in the vacuum chamber. Micrographs of chitosan cross-section
demonstrate a porous fibre structure filled with water in the wet state and smooth and
dense structure after dehydration[118].

Figure 3-9 SEM image a) cross-section of hydrated 3% w/v chitosan wet-spun (inset
higher magnification of cross-section of hydrated 3% w/v chitosan), b) surface of 3%
w/v chitosan in the hydrated state, c) cross-section, and d) surface of 3% w/v chitosan
in dry state. Fibres spun in 1M NaOH in water/ethanol 90/10 v/v coagulation bath.
3.6.1.3 Mechanical Properties of chitosan fibres
The Young’s modulus of 2% w/v and 3% w/v chitosan fibres were studied using a
standard tensile test. A slight difference in the Young’s modulus was observed when
the concentration of chitosan was increased; at 2% and 3% w/v concentration levels,
the Young’s modulus was 2.7 ± 0.4 GPa and 3.4 ± 0.8 GPa respectively. The increase
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in the Young’s modulus confers a decrease in fibre flexibility resulting in a more brittle
chitosan fibre.
Figure 3-10 outlines the difference in the stress-strain curve of chitosan fibres formed
from two different concentrations at a constant spinning condition. Chitosan (3% w/v)
wet-spun fibres exhibited a higher elongation at break (6.1 ± 0.8 %) compared with
2% w/v chitosan which had 3.9 ± 0.3% elongation at break. Elongation at break
expresses the change of final and initial length of fibre after breakage and can be
increased by increasing the chitosan concentration.

Figure 3-10 Stress-strain curve obtained from tensile tests of 2% w/v and 3% w/v
chitosan fibres
3.6.2

Alginate Fibres

3.6.2.1 Wet-spinning of alginate fibres
A rotary bath (Figure 3-7) containing 2% w/v CaCl2 in 20% v/v EtOH was used to
spin alginate fibres. EtOH was selected to accelerate the coagulation process by
dehydrating the alginate.
Calcium chloride (CaCl2) is one of the most commonly used agents to cross-link
alginate. Calcium sulfate (CaSO4) and calcium carbonate (CaCO3) are the alternative
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options for cross-linking. Due to their lower solubility in water at neutral pH, they can
reduce the gelation rate. The process is explained below.
Two G blocks of the polymer can be cross-linked with divalent cations (e.g., Ca2+or
Ba2+)[108]. An alginate solution can be mixed with CaCO3, followed by addition of
Glucono-δ-lactone to the mixture, resulting in the disassociation of Ca2+ from the
CaCO3 by lowering the pH. The released Ca2+ then initiates the gelation of the alginate
solution at a slow rate[119].

Figure 3-11 In the presence of divalent calcium ions, the calcium chelates to the
carboxylate ions. The result is a chain of calcium-linked alginate which forms a gel[120].
Different concentrations (0.5-3.5% w/v) of alginate solution were prepared by mixing
alginic acid sodium salt (medium molecular weight) with de-ionized water and stirring
the resulting mixture for 24 h at 50 ºC. The coagulation solution used was 2% w/v
calcium chloride (CaCl2) which has been reported as a standard coagulation solution
for alginate[120]. Using CaCl2 it was possible to form fibres from 1% to 3.5% w/v
alginate. Since a higher concentration of alginate is able to encapsulate a larger
percentage of drug, 3.5% w/v of alginate was used for our studies described in this
thesis. This concentration of alginate was the upper threshold that facilitated formation
of wet-spun fibres and it was used in the formation of coaxial PCL/Alg fibres (section
3.10.2)[121].
Alginate fibres were spun in a long bath using the injection flow rates of 5 mL.h-1, 15
mL.h-1, and 50 mL.h-1. The fibres were then retained in de-ionized water to be washed
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and dried at room temperature. Figure 3-12 shows the optical image of dry alginate
fibre, and Table 3-6 shows that the diameter of 3.5% w/v alginate fibres increased
with constant spinning by increasing the solution’s flow rate from 5 to 50 mL.h-1.

Figure 3-12 Optical image of dry 3.5% w/v alginate fibre spun in 2% CaCl2
coagulation bath with 5 mL.h-1 flow rate.
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Table 3-6 Effect of flow rate on diameter of 3.5% w/v wet-spun alginate fibre at dry
state.
Flow rate (mL.h-1)

Fibre Diameter (µm)

5

99.3 ± 0.6

15

113.2 ± 1.7

50

167.5 ± 1.4

3.6.2.2 Morphological Properties of Alginate Fibres
When a dehydrated fibre is rehydrated in an aqueous solution, the diameter of the fibre
returns to the initial as-spun hydrated diameter. Figure 3-13 shows the 3.5% w/v
alginate fibre in dry (a), rehydrated (b) states and demonstrating that the 3.5% w/v
alginate wet-spun fibre has a smooth cross-section area when fully hydrated. It is clear
that the shape of the cross-section is significantly varied during the dehydrating
process. However, by rehydrating the fibre, the circular cross-section is regained as
shown in Figure 3-13 (b). Alginate fibres like chitosan fibres have porous and spongy
cross-sections filled with water in the wet state that has potential for future applications
as a drug carrier[40] (Figure 3-13 b inset).

Figure 3-13 SEM image of 3.5% w/v alginate fibre a) dehydrated, b) rehydrated state,
and inset) higher magnification of hydrated alginate fibre.
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3.6.2.3 Mechanical properties of alginate fibres
The effect of injection flow rate on the mechanical properties of alginate fibres was
studied. The mechanical properties of fibres produced from a solution of 3.5% w/v
alginate formed at different flow rates (5-50 mL.h-1) is shown in Figure 3-14.
Observation of stress-strain curves reveals that mechanical properties of fibres are
affected by the spinning conditions. Young’s modulus values of these fibres was
deduced from the initial most linear part of the curves (Figure 3-14). The young’s
modules of the alginate fibres increased from 0.8 ± 0.1 GPa to 2.1 ± 0.1 GPa and 4.1
± 0.7 GPa when the flow rate of alginate spinning solution was increased from 5 to 50
mL.h-1, respectively. Moreover, the ultimate stress increased while elongation at break
did not change significantly.

Figure 3-14 Stress-strain curve of 3.5% w/v alginate fibre wet-spun in three different
flow rates.
The results of wet-spun fibres in different solvent and non-solvent, PCL-DMF/water
appear to have improved properties in comparison with others. Moreover, these fibres
are readily spinnable in water at a higher coagulation rate. Therefore, for coaxial fibres
which will be discussed in the next section, PCL-DMF/water was utilised as a sheath
of coaxial fibre.
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3.7

Wet-spinning of Coaxial Fibres

The next stage of the thesis presents the work undertaken to form coaxial
PCL/hydrogel fibres. Prior to forming these coaxial fibres it was important to gain an
understanding on how the PCL fibre forms by coaxial spinneret. Initially PCL hollow
fibres were fabricated and characterised, followed by PCL/alginate and then finally
PCL/chitosan coaxial fibre spinning and characterisation.
3.7.1

PCL hollow fibres

Preliminary studies of formation of hollow PCL coaxial fibres were performed prior
to attempting to co-axially wet-spin PCL/CS and PCL/Alg coaxial fibres. The
optimized coaxial wet-spinning method used to wet-spin these hollow PCL fibres is
shown in Figure 2-2. To form such hollow fibres, the PCL solution was used as a
sheath and water was used as the core. The hollow PCL fibres were wet-spun at a flow
injection rate of 15 mL.h-1 and collected at a speed of 30 rpm. The fibres were dried in
a vacuum oven for 24 h at 50 °C. The fibres were wet-spun by spinneret with the
diameter of 1.309 mm as shown in Figure 3-15. The geometry of nozzle plays an
important role in the morphology of the fibre. Any deformation or scratch on the wall
of the nozzle may change the circular shape of the fibre to an irregular shape.

Figure 3-15 Microscopic image of coaxial spinneret’s shell.
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3.7.1.1 Morphology characterization of hollow PCL fibre
In order to obtain an appropriate fibre diameter and morphology, SEM and optical
microscopy analyses was performed on the hollow PCL fibres. Fibres with a diameter
of 1.3 ± 0.1 mm were obtained however through variation of uptake speed of the
collector and flow rate the wall thickness of hollow fibres can be adjusted. By
increasing the speed of collector, fibre diameter, as well as wall thickness, decreased.
The total diameter of fibre reduced to 70.1 ±4.2 µm.
As shown in Figure 3-16 (a), wall thickness of the hollow fibre was non-uniform. This
was due to the core nozzle not positioned in the exact centre of the sheath. The
spinneret used to wet-spin the fibre is shown in Figure 3-16 (b).
SEM images showed that the cross-sectional area of the PCL hollow fibre was
perfectly circular; the fibre holds the circular shape of the extrusion tip. The PCL
hollow fibre was porous and a dense support layer between its inner and outer skin had
been formed (Figure 3-17 (b)). A microporous morphology has been created on both
sides of the inner boundary. Since PCL fibre was in contact with coagulation bath at
its inner and outer sides (Figure 3-17), a skin layer was formed at both sides. In
contrast, the PCL solid wet-spun fibre (Figure 3-3) consists of outer skin (a dense
layer) only, a boundary layer has not been created and the internal structure is porous.

Figure 3-16 a) SEM image of hollow PCL wet-spun fibre by the co-axial wet-spinning
method, and b) microscopic image of spinneret used to wet-spin PCL hollow fibre.
The needle is not adjusted in the centre of the sheath.
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Figure 3-17 SEM cross section image of a) PCL hollow fibre, and b) PCL hollow fibre
wall with higher magnification.
PCL hollow fibres were successfully wet-spun (injection flow rate of 15 mL.h-1). Wetspinning parameters such as spinneret adjustment, coagulation bath, washing bath, and
injection flow rate were optimised to allow for the fabrication of continuous and
uniform PCL hollow fibres. The SEM images of these fibres showed highly
microporous structures. The following step involved replacing the water core with
hydrogels to fabricate PCL/hydrogel coaxial fibres.
3.7.2

PCL/Alg and PCL/CS Coaxial Fibres

3.7.2.1 Wet-spinning of PCL/Alg and PCL/CS Coaxial Fibres
PCL/Alg coaxial fibres were produced by using PCL and alginate solutions in
individual syringes. Coaxial fibres were fabricated by the wet spinning process as
shown in Figure 2-2. Different injection flow rates were used for both the core and
sheath to obtain a desirable structure. In order to produce a continuous coaxial fibre,
many parameters must be considered. The most important parameters are coagulation
bath and flow rate of the injected solution. The selected coagulation bath must
coagulate both the core and sheath simultaneously, which means that it is necessary
that coaguation bath diffuses into the core in order to coagulate the inner spinning
solution. Therefore, the morphology of the fibre should also be considered. In this
study PCL has a porous structure (Figure 3-17) which allows the coagulation bath
solution to diffuse into the core in order to coagulate the core material. As PCL
coagulates in water, the core solution plays an important role in selecting the
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coagulation bath solution. 2% w/v CaCl2 was usedas a coagulation bath for PCL/Alg
coaxial fibres, since CaCl2 is a commonly used cross-linker for alginate, and PCL can
be coagulated by water only. Figure 3-18 shows that unlimited lengths of fibre can be
produced by coaxial wet-spinning.

Figure 3-18 Photograph of unlimited continuous length of coaxial PCL/Alg fibre in
the coagulation bath of 2% w/v CaCl2. Flow rate of core = 10 mL.h-1, sheath flow rate
= 10 mL.h-1.
The applied injection flow rate was 10 mL.h-1 (core), and 10 mL.h-1 (sheath) for coaxial
fibres However, different injection flow rates were applied to optimise the wetspinning condition in order to obtain reproducible coaxial fibres.
Since the PCL fibres are not transparent it was difficult to ensure that the fibre
contained hydrogel. Two different approaches were tried to better visualise the
formation of a core in the PCL fibre. Firstly Toluidine Blue dye was used in the core
solution (alginate). The colour due to the dye was obvious during the wet-spinning
process, however, when the PCL fibre dried its core was not clearly visible through
the surface of the fibre, it was only able to be seen from a cross-section of the fibre. In
order to take optical images of the fibre to highlight the core clearly (Figure 3-19), a
few drops of DMF (PCL solvent) were placed on the fibre, dissolving a thin layer of
the sheath to reveal the core (Figure 3-19 (a)). The PCL/CS fibre did not contain the
dye in the cross-section, however the core is still obvious (Figure 3-19 (d)).
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Figure 3-19 Optical microscopic surface images of a) PCL/Alg and b) PCL/CS coaxial fibre. TBO (Toluidine Blue O) dye has been added to alginate in order to be
easily visible, and cross-section images of c) PCL/Alg and d) PCL/CS wet-spun
coaxial fibre immediately after spinning.
The cross-section of coaxial fibres can be readily seen in the wet and dry state (Figure
3-19 (c and d)). It must be noted that imaging must occur immediately after wetspinning in order to see the hydrated hydrogel core. To prevent the fibres from drying
out they must be kept in PBS or water. Figure 3-20 shows the fibres that were kept in
water for 30 min after spinning and clearly show the hydrogels swell when they absorb
water resulting in the core pertruding from the fibres (from cross-section).
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Figure 3-20 Optical microscopic images of a) PCL/Alg and b) PCL/CS wet-spun
coaxial fibres immediately after spinning while stored in water for 5 min. Hydrogel
absorbing water resulting in swelling and protrusion of the core.
3.7.2.2 Morphological Properties of PCL/Alg coaxial wet-spun fibre
The effect of flow rate on the morphology of PCL/Alg coaxial fibres was investigated
at constant draw ratio by measuring the fibre diameter through SEM. Measuring the
core diameter in SEM is inaccurate as dehydration occurs during the imaging process
(Figure 3-24). Therefore, to measure the core diameter an optical microscope must be
used as shown Figure 3-21. To image the coaxial fibres, they must be placed into
liquid nitrogen immediately after spinning to avoid dehydration. Figure 3-21 shows
optical images taken while the fibres were mounted on a specimen holder and placed
into a petri dish containing liquid nitrogen. In this study, our focus was on sheath
diameter (PCL), therefore SEM was the best choice for analysis. The results
demonstrated that increased sheath flow rate yielded an increase in total fibre diameter
(Figure 3-23). The total fibre diameter increased from 363.2 ± 56.1 µm to 534.5 ±
74.2 µm and 596.3 ± 110.2 µm by an increase in flow rate of sheath from 10 to 30 and
40 mL.h-1, respectively, at constant 10 mL.h-1 core flow rate. In contrast, increasing
the core flow rate (at a constant sheath flow rate) did not significantly change the total
fibre diameter, but the diameter of sheath decreased. Due to the flexibility of PCL, it
can be easily affected by the core flow rate and it becomes thinner by increasing the
core flow rate. Figure 3-22 shows the effect of core flow rate on the diameter of the
sheath. The sheath diameter decreased from 25.3 ± 0.6 to 3.6 ± 0.7 µm when the core
flow rate increased from 10 to 20 mL.h-1 at a constant 10 mL.h-1 flow rate of the sheath
and constant drawing ratio. Moreover, at a constant flow rate of 30 mL.h-1, the sheath
diameter decreased from 46.7 ± 2.2 to 11.4 ± 1.7 µm when core flow rate increased
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from 100 to 200 mL.h-1. By increasing the flow rate of the core from 100 to 200 mL.h1

(at a constant sheath flow rate of 40 mL.h-1), the sheath diameter decreased from 58.4

± 1.3 to 10.3 ± 1.9 µm. Table 3-7 summarises the above mentioned data.
Table 3-7 Summary of the total and sheath diameters of fibres at various sheath and
core flow rates
PCL/Alg coaxial fibre
Sheath flow

Core flow rate

Total Diameter

Sheath Diameter

10

10

363.2 ± 56.1

25.3 ± 0.6

10

20

371.1 ± 48.3

3.6 ± 0.7

30

100

534.5 ± 74.2

46.7 ± 2.2

30

200

548.1 ± 3.4

11.4 ± 1.7

40

100

596.3 ± 110.2

58.4±1.3

40

200

609.4 ± 99.7

10.3 ± 1.9

rate

Figure 3-23 illustrates the SEM images of coaxial PCL/Alg fibres produced at varying
core and sheath flow rates. In summary, changing the flow rate during the wet-spinning
process produces fibres with different diameters. To obtain fine fibres with diameters
of 100-300 µm, a lower flow rate must be used. However, this results in the sheath
having a larger diameter and in turn diffusion of the cross-linker (e.g., CaCl2) into the
core becomes difficult. Therefore, another cross-linker was considered. Experiments
were performed to overcome this obstacle, described later in this thesis.
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Figure 3-21 Optical microscope cross-section images of a) PCL/Alg wet-spun fibre,
and b) PCL/CS wet-spun fibre in liquid nitrogen immediately after wet-spinning.
PCL (sheath) and Alg (core) fibres do not interact in coaxial fibres after the drying
process (Figure 3-24(c)). This can be expected as PCL is hydrophobic, while alginate
is hydrophilic. The surface charge may also be another factor as both PCL and alginate
have a negative surface charge, or it may be due to the different shrinkages are obtained
for PCL and alginate. When the coaxial fibre is rehydrated in PBS or water it returns
to its initial structure. Figure 3-24 shows the PCL/Alg wet-spun coaxial fibre in the
wet and dry state.

55

Figure 3-22 Effect of core flow rate on the sheath diameter at a constant drawing ratio
and constant sheath flow rate
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Figure 3-23 SEM images of hydrated PCL/Alg wet-spun fibre with a) 40 mL.h-1 flow
rate of Sheath and 100 mL.h-1 flow rate of core, b) 40 mL.h-1flow rate of sheath and
200 mL.h-1 flow rate of core, c) Sheath flow rate: 30 mL.h-1 and core flow rate: 100
mL.h-1, d) sheath flow rate: 30 mL.h-1 and core flow rate: 200 mL.h-1, e) sheath flow
rate: 10 mL.h-1 and core flow rate: 10 mL.h-1, and f) sheath flow rate:10 mL.h-1 and
core flow rate: 20 mL.h-1 at a constant draw ratio in 2% CaCl2 coagulation bath.
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Figure 3-24 SEM image of PCL/Alg fibre in a) wet state, b) same PCL/Alg fibre after
5 minutes in SEM chamber, and c) completely dry PCL/Alg fibre.
3.7.2.3 Morphological Properties of PCL/CS Wet-spun Fibre
The Effect of flow rate has been investigated on the morphology of PCL/CS wet-spun
fibres by maintaining a constant sheath flow rate (25 mL.h-1) then increasing the core
flow rate effect on the total diameter of fibre as well as sheath diameter were studied.
Figure 3-25 shows the SEM image of PCL/CS fibres which core flow rate increase
from 5 mL.h-1 (Figure 3-23(a)) to 15 mL.h-1 (Figure 3-25(b)). The cylinder shape of
the fibre is intact in the dry state. Moreover, the PCL fibre has not changed in dry
condition however the chitosan hydrogel core appeared to attach to the inner wall of
the PCL fibre, losing its fibrous structure under dehydration conditions. The fibre total
diameter increased from 545.0 ± 19.5 µm to 597.0 ± 61.1 µm, however, the diameter
of sheath (wall thickness) decreased from 93.6 ± 31.0µm to 68.9 ± 14.2 µm when the
core flow rate increased from 5 to 15 mL.h-1 (constant sheath flow rate (25 mL.h-1)).
From these results, it appears that a flow rate of 25/5 mL.h-1 of sheath/core is the ideal
flow rate to obtain a fibre with a total diameter of 100-200 µm. Table 3-8 summarises
the above mentioned data.
Table 3-8 Summary of the total and sheath diameters of fibres at various sheath and
core flow rates
PCL/CS coaxial fibre
Sheath flow
rate

Core flow rate

Total Diameter

Sheath Diameter

25

5

545.0 ± 19.5

93.6 ± 31.0

25

15

597.0 ± 61.1

68.9 ± 14.2
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Figure 3-25 SEM image of dry PCL/CS fibre, a) wet-spun with sheath flow rate of 25
mL.h-1 and core of 5 mL.h-1 and inset higher magnification of interaction between
chitosan and PCL and b) sheath flow rate: 25 mL.h-1 and core flow rate: 15 mL.h-1 in
1M NaOH coagulation bath and inset higher magnification of chitosan attached to PCL
wall.
After drying, the chitosan fibre attached to the wall of the PCL fibre. However, in the
case of a dry wet-spun PCL/Alg fibre (Figure 3-24 (c)) the alginate maintained its
fibrous structure and completely detached from the PCL.
To ensure that coaxial PCL/CS fibres maintain a fibrous structure in wet conditions,
completely dry fibre was placed into PBS for 24 h. Figure 3-26 (a) shows the dry fibre
and Figure 3-26(b) shows the fibre rehydrated for 24 h. It is clearly visible that the
fibre returned to its initial structure.

Figure 3-26 SEM image of PCL/CS wet-sun fibre in a) dry state and b) rehydrated
state. Fibres were spun with a flow rate of sheath: 25 mL.h-1 and core: 5 mL.h-1.
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3.7.2.4 Mechanical Properties of PCL/Alg and PCL/CS wet-spun fibres
Mechanical properties of PCL/CS and PCL/Alg coaxial fibres have been studied in
order to calculate Young’s modulus of fibres, primarily to examine the elasticity of
fibres. In order to utilise fibres in future applications, fibres must be soft, flexible, and
easy to handle; by lowering Young’s modulus softer fibres can be produced. The
Young’s modulus of fibres was calculated from the linear part of the curve. The
Young’s modulus of PCL/Alg wet-spun coaxial fibre was calculated to be 2.31 ± 0.38
MPa and PCL/CS wet-spun fibres gave Young’s modulus of 0.66 ± 0.07 MPa.
Young’s modulus values of coaxial fibres decreased significantly in comparison to
solid individual fibres. Figure 3-27 (a and b) show the stress-strain curves of coaxial
fibres; both graphs depict a sudden drop after approximately 40-80% strain. The first
decrease in the stress/strain curve corresponds to breakage of the core (chitosan and
alginate fibre), and due to the larger elongation at break of PCL fibres, second breakage
of fibre shows PCL elongation at break. The PCL/CS coaxial fibres exhibited an
increase in the first elongation at break from approximately 6.15% to 80%. This
significant increase may be due to the change in fibre morphology in the coaxial state.
The shape of the chitosan fibre in the coaxial state post drying changed from a circular
fibrous structure to a hollow chitosan fibre. Moreover, after drying the chitosan fibre
attached to the PCL fibre wall which is possibly due to a chemical interaction.
However, the change of the first elongation at break in the PCL/Alg coaxial fibre in
comparison to alginate solid fibre was negligible. This is expected as the PCL/Alg
coaxial fibre became detached after drying. The fibre morphology was similar to the
PCL hollow fibre with one alginate fibre within. The total elongation at break of
coaxial fibres is similar to the PCL individual fibre.
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Figure 3-27 Stress-strain curve of a) coaxial PCL/CS wet-spun fibres, and b) coaxial
PCL/Alg wet-spun fibres.
3.7.2.5 In-vitro Release Measurement of TBO from PCL/Alg and PCL/CS wet-spun
fibres
The release of TBO (Toluidine Blue O) from PCL/Alg and PCL/CS coaxial wet-spun
fibres was performed in PBS (pH~7.4) at 37 °C by placing 4.0 cm of coaxial fibre
containing dye within the core. The released PBS medium was collected by
micropipette at specific time points and replaced with the same volume of fresh PBS
solution. The calibration curve was determined by monitoring the absorption of TB
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(Toluidine Blue) at its λmax (630 nm). The established standard curve for determining
TB concentration in PBS solution was y = 0.00268 + 0.03785*x and R2 = 0.99788 as
shown in Figure 3-28.

Figure 3-28 Calibration curve of TBO in PBS.
The loading efficiency of TB per 1.0 cm was estimated by dissolving 1.0 cm length of
fibre in PBS solution. The TB concentration was obtained by UV-Vis spectroscopy
and cumulative TB release data plotted as a percentage of (Mt) release relative to the
TB loading (Mtot).
The release profile of TBO from loaded coaxial and solid fibres were plotted relative
to time and are shown in Figure 3-29. The release was monitored for 3 weeks, however
no additional TB was released from the fibre. Three samples from each fibre were
examined and the curve obtained represented the average of the three samples. The
alginate fibre readily dissolved in PBS (within one hour) due to the ion exchange
between the fibre and media, resulting in its structure falling apart. However, PCL as
a protector sheath prevented the fibre from collapsing the alginate structure in 1 hour.
PCL delayed disintegration of the alginate structure, which affected release of TB from
alginate fibre. Therefore, PCL/Alg coaxial curve reached a plateau after 4.5 hours as
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shown in Figure 3-29. Not all the TB was released from the Alg fibre, although it
completely dissolved in PBS as shown in Figure 3-29. This may be due to the uneven
distribution of TB in the whole fibre with some TB possibly trapped within the PCL
porous structure. The delay in the release of PCL/CS coaxial fibre in comparison with
PCL/Alg fibre is significant (inset Figure 3-29); PCL/CS coaxial fibre reaches a
plateau after 17 hours whereas the CS solid fibre ceased its release after 4 hours
(Figure 3-29).

Figure 3-29 Cumulative masses of TB released from the 3% w/v chitosan, 3.5% w/v
alginate solid fibres, and PCL/Alg and PCL/CS coaxial wet-spun fibre and inset is the
total of 300 hours of release.
These results demonstrate the capability of coaxial fibres as potential drug carriers.
Both hydrophobic and hydrophilic drugs can be loaded either into the PCL
(hydrophobic) or into CS and Alg (hydrophilic) fibres. Release profiles may improve
by replacing the different types of cross-linkers with coagulation bath.
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3.7.2.6 Effect of cross-linker on morphology of PCL/Alg fibres
Using a coagulation bath to crosslink the core of coaxial fibres was challenging when
the diameter of the sheath increased. Therefore, addition of a cross-linker dissolved in
the core was tried to overcome this issue.
CaSO4 and CaCO3 are commonly used Ca2+ sources that rely on internal gelling
through the release of calcium ions. CaCO3 was added to 3.5% w/v alginate solution,
yielding a 15 mM final concentration just before extrusion and the solution vortexed
for 30 s to allow the homogeneous distribution of CaCO3. Glucono-δ-lactone (GDL)
(30 mM) was then added to the alginate/ CaCO3 solution just before fibre extrusion.
CaCO3 is not readily soluble in water at neutral pH and since calcium ions are not free
when was added to the alginate solution, gelation was not initiated. Mixing with GDL
improved CaCO3 solubility as GDL slowly acidified the alginate/ CaCO3, driving the
release of calcium ions. Gelation started 30 min after addition of GDL[122,123]. Figure
3-30 shows the cross-section morphology of wet-sun fibres using CaCl2 as alginate’s
cross-linker, compared to the PCL/Alg coaxial fibre with CaCO3/GDL cross-linker.
This method allowed us to alter the sheath diameter, allowing more control over
formation of the hydrogel structure.

Figure 3-30 LV-SEM images of a cross-section of a) PCL/Alg coaxial fibre in CaCl2
coagulation bath, b) PCL/Alg coaxial fibre in a water bath and using CaCO3/GDL as
a cross-linker, and c) higher magnification of alginate fibre in wet-state.
3.7.2.7 Effect of cross-linker on morphology of PCL/CS fibre
The crosslinking of CS has been reported with crosslinkers such a glutaraldehyde
(GA)[124], genipin[125], and epoxides[126]. However, besides genipin, these crosslinking
agents are synthetically derived. Genipin is naturally derived, biocompatible crosslinker which has 5000 –10,000 times less cytotoxicity than GA[125]. Genipin reacts
with compounds containing primary amines, such as chitosan, to form covalently
crosslinked networks[77]. Figure 3-31 shows chemical structure of genipin.
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Figure 3-31 Genipin chemical structure.
In our wet-spun chitosan fibres, crosslinking occurred by altering the pH of chitosan.
1M NaOH was used as coagulation bath (pH~12), promoting the crosslinking of
chitosan. However, this method has drawbacks such as difficulty in removing NaOH
from the fibre and difficulty in diffusing the NaOH by increasing the sheath diameter
in coaxial fibre. Genipin may overcome these drawbacks. In this experiment, genipin
was dissolved in acetic acid then varying concentrations of genipin (100 mM to 400
mM) were added to the chitosan solution and the resulting solutions stirred for 30 min.
The reaction mechanism of chitosan with genipin is based on two reactions that
proceed at different rates: the first is a nucleophilic attack on genipin by a primary
amine group that leads to the formation of a heterocyclic compound of genipin linked
to the glucosamine residue in chitosan, and the second and slower reaction is the
nucleophilic substitution of the ester group possessed by genipin to form a secondary
amide link with chitosan. Figure 3-32 shows the cross-section morphology of coaxial
fibre before and after addition of genipin. A slight change in morphology of the sheath
(PCL) in PCL/CS coaxial fibre wet-spun in NaOH coagulation bath was observed.
Since removing the NaOH from the fibre was challenging, it can result in damage to
the morphology of PCL. Moreover, diffusion of NaOH into the core proved difficult
when increasing the sheath diameter. However, addition of genipin into the core
(chitosan) enabled complete crosslinking of chitosan, yielding an intact fibre.
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Figure 3-32 LV-SEM images of cross-section of a) PCL/CS coaxial fibre in 1M NaOH
coagulation bath, b) PCL/CS coaxial fibre in a water bath with genipin as a crosslinker, c) higher magnification of chitosan fibre in wet-state, and d) higher
magnification of PCL/CS interface in coaxial fibre.

The gelation time of chitosan was crucial for wet-spinning and was obtained through
rheology studies. Liquid samples (chitosan solution) were transferred into a rheometer
plate immediately after mixing (t = 0). The time sweeping procedure was used to test
samples and the measurement stopped at 500 min. Gelation time was measured by
cross-point of Storage moduli G′ and loss moduli G′′. Figure 3-33 shows the storage
modulus (G′) and loss moduli (G′′) as a function of time (t) for genipin at various
concentrations (100-400 mM). The results showed that 200 mM and 400 mM are ideal
concentrations of genipin for wet-spinning. Gelation of chitosan began after
approximately 1 hour of mixing 100 mM genipin, and 20 min for 400 mM genipin,
therefore, genipin must be added immediately before extrusion (Table 3-9). This
method may remove limitations of altering the diameter of sheath and washing process
of fibres. This is important as the washing process may inadvertently wash out drugs
from within the fibre-containing drug carrier.
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Figure 3-33 Storage modulus (G′) and loss modulus (G′′) as a function of time (t) for
genipin in different concentration.
Table 3-9 Gelation time of chitosan solution after addition of different concentration
of genipin.
Sample

Gelation time (min)

100 mM genipin

182.45

200 mM genipin

66.59

400 mM genipin

19.64
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4

CONCLUSIONS AND FUTURE WORK

The main aim of this thesis was to develop biodegradable coaxial fibres based on wetspinning method for biomedical applications. Coaxial PCL/Alg, and PCL/CS wet-spun
fibres were fabricated for the first time using coaxial wet-spinning method. The
spinnability, morphological, mechanical, and thermal properties of fibres were studied.
The solubility of PCL was investigated in THF, DMF, acetone, DCM, EtOH, MetOH,
IPA, and chloroform.
The results showed that PCL is soluble in THF, DCM, DMF, acetone, and chloroform.
Different concentration of PCL (5-20% w/v) was dissolved in DCM, acetone, DMF,
and chloroform. PCL (15% w/v) in DMF, DCM, and acetone or 20% w/v PCL in
chloroform are suitable concentration levels for obtaining continuous, uniform fibres.
After selecting the suitable solution, the desirable coagulation bath was chosen for
each fibre. Water was used as a PCL/DMF coagulation bath and MeOH/water 70/30
v/v was used as the non-solvent for PCL dissolved in DCM and chloroform.
Water/EtOH 70/30 v/v was used as PCL/acetone coagulation bath.
Fibres with different diameters were produced. Their diameter can be altered by
varying the flow rate and needle gauge. Morphological properties of these four PCL
fibres were studied. PCL/DMF fibre has a porous cross-section structure with pore
sizes larger than the ones in PCL/acetone fibres. Such porous structures of PCL/DMF
and PCL/acetone show potential advantages for future drug delivery applications.
PCL/DCM and chloroform fibres had a dense structure. To utilise fibres in a
biomedical application, their mechanical properties must be investigated.
According to our study, PCL/DMF fibre have a lower Young’s modulus of 18.2 ±
1.2MPa, and then PCL/acetone fibre’s Young’s modulus is 98.9 ± 14.3 MPa,
PCL/DCM fibres have the highest Young’s modulus of 214.9 ± 55.1MPa. Young’s
modulus in fibres shows their stiffness. Fibres with lower Young’s modulus are softer.
Therefore, they are easy to handle and most importantly they may be compatible with
soft tissues in terms of mechanical properties. Body tissues that are classified as soft
tissues exhibit significantly lower Young’s modulus.
PCL/DMF and PCL/acetone fibres have larger elongation of about 400-500% at their
break point. This result shows that by stretching the fibres, their mechanical properties
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can be improved and their diameter can be decreased. Due to the PCL/DMF and
PCL/acetone fibres’ better properties, thermal characteristics of these two fibres were
compared with PCL pellets. The results showed that the solvent does not affect the
melting point of the PCL but changes its % crystallinity.
Spinnability of different concentrations of chitosan was examined. The results showed
that 3% w/v chitosan had the best spinnability and mechanical properties. Chitosan
fibres were spun in 1M NaOH in water/ethanol 90/10 v/v coagulation bath.
This produced fibres with a diameter of 193.6 ± 6.1 µm. SEM images of the fibres
showed that chitosan has a smooth surface with a porous cross-section structure in
wet-state. This means that it is a suitable candidate for drug delivery structures. There
is a slight difference between 2% and 3 %w/v chitosan Young’s modulus (2%: 2.7 ±
0.4 GPa and 3%: 3.4 ± 0.8 GPa). Chitosan (3% w/v) has a larger elongation break.
Chitosan fibres in the dry state are brittle and difficult to handle due to their larger
Young’s modulus. The other hydrogel that has potential to be utilise as a core in
coaxial fibre is alginate. 0.5-3.5% w/v range of concentration of alginate was prepared
and spinnability of these solutions was investigated. 2-3.5 %w/v alginate is spinnable
in 2% CaCl2 in 20% v/v EtOH. Due to the higher loading capacity of 3.5% w/v
alginate, further characterization was conducted with this concentration. A spinning
condition such as flow rate, draw ratio, and solvent/non-solvent combination has a
large impact on the properties of wet-spun fibres. In order to investigate the effect of
flow rate on wet-spun fibres, 3.5% w/v alginate fibres were wet-spun with three
different flow rates of 5, 15, and 50 mL.h-1. Higher flow rate results in higher Young’s
modulus and firm fibres. Flow rate has an impact on ultimate stress but doesn’t affect
fibre’s elongation at break.
Hollow PCL, PCL/Alg, and PCL/CS coaxial fibres were successfully fabricated by
wet-spinning with coaxial spinneret. Coagulation bath was chosen according to the
core material. 2% CaCl2 and 1M NaOH were used as a coagulant of PCL/Alg and
PCL/CS coaxial fibres. Unlimited length of fibres was fabricated by this method. SEM
and optical images of the cross-section of PCL/Alg and PCL/CS showed a cylinder
shaped hydrogel covered with PCL sheath. The effect of the core flow rate on the
diameter of the fibre and the sheath was studied. By increasing the core flow rate, the
total diameter of fibres increases while the dimeter of sheath decreases. Hydrated,
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dehydrated, and rehydrated states of these fibres were imaged and showed that the
fibres return to their initial state by placing in PBS or water.
The mechanical properties of PCL/Alg and PCL/CS coaxial wet-spun fibres were
discussed. Coaxial fibres still have a low Young’s modulus that shows the possibility
of compatibility with body’s soft tissues in future biomedical applications. Coaxial
fibres are capable of being loaded with either hydrophilic or hydrophobic drugs as
TBO release studies were done. TBO was used as a model to investigate the release
profile of coaxial fibres against hydrogel solid fibres. Since hydrogels have a burst
release, PCL fibre as a hydrophobic structure covers the alginate and chitosan structure
to prevent them from falling apart and burst releasing.
The release of TBO is delayed by using PCL as a sheath. However, this can be
improved and more delayed by optimising the structure. The diameter of the sheath
can be increased by altering the flow rate, however, the only obstacle here is the
difficulty with diffusing the coagulation bath into the core to cross-link the hydrogel.
To overcome this obstacle, other types of cross-linkers were utilised to ensure that by
increasing the diameter of sheath, hydrogels can still be cross-linked. CaCO3/GDL was
incorporated into the alginate solution and genipin was incorporated into the chitosan
solution immediately before fibre extrusion. Rheology properties of the incorporation
of genipin into chitosan were investigated in order to obtain gelation time. Using
different concentration levels of Genipin, different gelation times were obtained.
Depending on the wet-spinning process duration, the gelation time can be adjusted.
FUTURE WORK
Since our proposed coaxial fibre demonstrated great potential toward drug delivery
system, further characterization must be performed. Next step to utilise coaxial fibres
is to integrate them into knitted or braided structures. Employing these assemblies
provide higher drug release efficiency. Anti-cancer drugs such as Gemcitabine,
Paclitaxel, and Doxorubicin can be incorporated into the coaxial fibre. FTIR analysis
must be conducted to investigate the possible interaction between the drug and the
polymer. Biocompatibility tests must be performed in order to improve the structure
as an implantable drug carrier. In-vivo and In-vitro release studies of real drugs from
coaxial fibre are also mandatory steps.
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